Suchergebnisse - "ter Haar, Nienke M"

PubPharm (36)

1

Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2024

von Erkens, R. | Calis, J. | Verwoerd, A. | +16

2

Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants

enthalten in: Arthritis & Rheumatology | 2024

von Erkens, R. | Calis, J. | Verwoerd, A. | +16

3

Developing Entrustable Professional Activities for the Training of Translational Scientists : A Modified Delphi Study

enthalten in: Academic medicine : journal of the Association of American Medical Colleges | 2021

von Weggemans, M. | Ter Haar, N. | Prakken, B. | +1

4

Response to : 'Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype' by Gupta et al

enthalten in: Annals of the rheumatic diseases | 2021

von Eijkelboom, C. | Ter Haar, N. | Frenkel, J. | +1

CommentOn: Ann Rheum Dis. 2019 Oct;78(10):1405-1411. - PMID 31278138

5

Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases

enthalten in: Annals of the rheumatic diseases | 2019

von Ter Haar, N. | Eijkelboom, C. | Cantarini, L. | +24

CommentIn: Ann Rheum Dis. 2021 Jul;80(7):e117. - PMID 31446425

6

Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis : Results From a Five-Year Follow-Up Study

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2019

von Ter Haar, N. | van Dijkhuizen, E. | Swart, J. | +12

CommentIn: Arthritis Rheumatol. 2019 Jul;71(7):1030-1033. - PMID 30802004

7

Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis : A Longitudinal Observational Cohort Study

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2019

von van Dijkhuizen, E. | Del Chierico, F. | Malattia, C. | +11

CommentIn: Arthritis Rheumatol. 2019 Jun;71(6):842-845. - PMID 30667170

8

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis : Results From a Five‐Year Follow‐Up Study

enthalten in: Arthritis & Rheumatology | 2019

von ter Haar, N. | Dijkhuizen, E. | Swart, J. | +12

9

In silico validation of the Autoinflammatory Disease Damage Index

enthalten in: Annals of the rheumatic diseases | 2018

von Ter Haar, N. | van Delft, A. | Annink, K. | +48

10

Prediction of inactive disease in juvenile idiopathic arthritis : a multicentre observational cohort study

enthalten in: Rheumatology (Oxford, England) | 2018

von van Dijkhuizen, E. | Aidonopoulos, O. | Ter Haar, N. | +8